Background/Aims: Little is known about how visceral adiposity and apolipoprotein CIII in apoB-containing lipoproteins influence atherogenic lipids profiles. The purpose of this study was to determine the relationships of visceral adiposity and apoC-III in apoB-containing lipoproteins (LpB:C-III) with lipoprotein lipids in circulating plasma. Methods: A subgroup of 46 men (n = 20, aged 29.1–33.4 years) and women (n = 26, aged 29.1–33.8 years) were recruited from an ongoing population study at our institution. Anthropometric variables including weight, height, and waist circumference were measured using standard procedures, and body mass index was calculated (kg/m2). Visceral adipose tissue (VAT) was measured with magnetic resonance imaging. Plasma apolipoproteins, lipids, glucose, and insulin were measured after an overnight fasting. Results: The men had a significantly higher waist circumference, glucose, and TC/HDL-C ratio, while the women had a significantly higher HDL-C and apoA-I. In particular, this is the first study to report that VAT and LpB:C-III were independent predictors in determining plasma triglyceride concentrations. Conclusion: The relations of plasma triglyceride concentration with VAT and LpB:C-III suggest that information on VAT and apoC-III in apoB-containing lipoproteins may provide additional information on the atherogenic lipid profiles.

Keywords:
Visceral adiposity, Plasma triglyceride, Apolipoprotein C-III
This content is only available via PDF.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.